个人简历

教育经历 研究机构/大学 学位 年份 专业及研究方向 美国国立卫生研究院 访问学者 2015-2016 细胞生物学 华东师范大学 博士 2006-2009 生物医学 美国德州农工大学 访问学者student 2007-2009 肿瘤与干细胞生物学 华东师范大学 硕士 2004-2006 资源植物化学 华东师范大学 学士 2000-2004 生物技术 工作及职称 2019.01—今 研究员，生命科学学院，华东师范大学 2012.08—2018.12 副研究员，生命科学学院，华东师范大学 2009.07—2012.07 讲师，生命科学学院，华东师范大学 荣誉 2018 上海市“浦江人才” 2016 中国“十大新锐科技人物” 2015 政府留学基金 2013 华东师范大学青年女教师成长资助金 2011 法国Biovision.Nxt会议基金 2010 上海市“晨光学者” 2009 华东师范大学优秀博士论文

近期论文

1. Jiang X, Lu Wei, Shen X, Wang Q, Lv J, Liu M, Chen F*, Zhao Z*, Pang X*. Repurposing the antidepressant drug sertraline: sensitizing non-small-cell lung cancer cells to erlotinib through induction of autophagy. JCI Insight. 2018,7;3(11). 2. Wu Z, Lu W, Yu W, Wang T, Li W, Liu G, Zhang H, Pang X, Huang J, Liu M, Cheng F, Tang Y. Quantitative and systems pharmacology 2. In silico polypharmacology of G protein-coupled receptor ligands via network-based approaches. Pharmacol Res. 2018;129:400-413. 3. Yu W, Lu W, Chen G, Cheng F, Su H, Chen Y, Liu M, Pang X*. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo. Br J Pharmacol. 2017; 174(20):3608-3622. 4. Jiang SH, Li J, Dong FY, Yang JY, Liu DJ, Yang XM, Wang YH, Yang MW, Fu XL, Zhang XX, Li Q, Pang XF, Huo YM, Li J, Zhang JF, Lee HY, Lee SJ, Qin WX, Gu JR, Sun YW, Zhang ZG. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice. Gastroenterology. 2017; 153(1):277-291. 5. Li K, Guo Q, Yang J, Chen H, Hu K, Zhao J, Zheng S, Pang X*, Zhou S*, Dang Y*, Li L*.FOXD3 is a tumor suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK signal pathway. Oncotarget. 2017, 8(3):5048-5056. 6. Guo J, Yu W, Su H, Pang X*. Genomic landscape of gastric cancer: molecular classification and potential targets. Sci China Life Sci. 2017, 60(2):126-137. 7. Pang X*, Liu M*. A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS. Chin J Cancer.2016, 35(1):92. 8. Pang X*, Liu M*. Defeat mutant KRAS with synthetic lethality. Small GTPases. 2016, 27:1-8. 9. Chen J, Guo J, Chen Z, Wang J, Liu M, Pang X*. Linifanib (ABT-869) potentiates the efficacy of chemotherapeutic agents through the suppression of receptor tyrosine kinases-mediated AKT/mTOR signaling pathways in gastric cancer. Sci Rep.2016, 6, 29382. 10. Guo J, Lv J, Chang S, Chen Z, Lu W, Xu C, Liu M, Pang X*. Inhibiting cytoplasmic accumulation of HuR synergizes genotoxic agents in urothelial carcinoma of the bladder. Oncotarget. 2016, 7(29):45249-4526. 11. Wang J, Hu K, Guo J, Cheng F, Lv J, Jiang W, Lu W, Liu J, Pang X*, Liu M*. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.Nat Commun. 2016, 7:11363. 12. Chen Y, Lv J, Li K, Xu J, Li M, Zhang W, Pang X*. Sporoderm-broken spores of Ganoderma lucidum inhibit the growth of lung cancer: Involvement of the Akt/mTOR signaling pathway. Nutr Cancer. 2016, 68(7):1151-60. 13. Wu Y, Wang X, Chang S, Lu W, Liu M, Pang X*. β-Lapachone Induces NAD(P)H:Quinone Oxidoreductase-1- and Oxidative Stress-Dependent Heat Shock Protein 90 Cleavage and Inhibits Tumor Growth and Angiogenesis. J Pharmacol Exp Ther. 2016, 357(3):466-75. 14. Li Z, Su H, Yu W, Li X, Cheng H, Liu M, Pang X*, Zou X*. Design, synthesis and anticancer activities of novel otobain derivatives.Org Biomol Chem. 2016, 7; 14(1):277-87. 15. Lv Jing, Wang J, Chang S, Liu M*, Pang X*. The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism? Acta Biochim Biophys Sin (Shanghai). 2016, 48(1):17-26.